

NCT ID	NCT03935893
Title	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Phase	Phase 2
Date Added	2019-05-02
Location	Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03069469
Title	Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase	Phase 1, Phase 2
Date Added	2017-03-03
Location	California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	DCC-3014
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04793958
Title	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Phase	Phase 3
Date Added	2021-03-11

Location	Alabama, United States
	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Louisiana, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	North Carolina, United States
	Ohio, United States
	Oklahoma, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Argentina
	Australia
	Austria
	Belgium
	Brazil
	Canada
	China
	Colombia
	Czechia
	Denmark
	Finland
	France
	Germany
	Greece
	Hong Kong
	Ireland
	Italy
	Korea, Republic of
	Malaysia
	Mexico
	Netherlands
	Poland
	Portugal
	Puerto Rico
	Romania
	Singapore
	Spain
	Taiwan
	Thailand
	Ukraine
	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT01697371
Title	Proton Therapy in the Treatment of Liver Metastases
Phase	Not Applicable
Date Added	2012-10-02
Location	California, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03650348
Title	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Phase	Phase 1
Date Added	2018-08-28
Location	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	PRS-343 in Combination with Atezolizumab, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT02537418
Title	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Phase	Phase 1
Date Added	2015-09-01
Location	Canada
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	durvalumab, Tremelimumab, Imfinzi
Tags	MSS/ MMRp
NCT ID	NCT02600949
Title	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Phase	Phase 1
Date Added	2015-11-09
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT04110093
Title	Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Phase	Phase 1/Phase 2
Date Added	2019-10-01
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Regorafenib and PD-1 inhibitor
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03668431
Title	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Phase	Phase 2
Date Added	2018-09-12
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03673787
Title	A Trial of Ipatasertib in Combination With Atezolizumab
Phase	Phase 1
Date Added	2018-09-17
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Atezolizumab, Ipatasertib
Tags	MSI-H/ MMRd, MSS/ MMRp